Cargando…
Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
Objectives: Pertuzumab is a monoclonal antibody for the treatment of breast cancer. The aim of this study was to compare the pharmacokinetics, immunogenicity and safety of the test preparation SHR-1309 injecta and the reference preparation Perjeta® in healthy Chinese male subjects. Methods: In this...
Autores principales: | Cui, Yingzi, Cui, Dongyang, Ren, Xinran, Chen, Xuesong, Liu, Guangwen, Liu, Zhengzhi, Wang, Yanli, Qu, Xinyao, Zhao, Yicheng, Yang, Haimiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207516/ https://www.ncbi.nlm.nih.gov/pubmed/34149414 http://dx.doi.org/10.3389/fphar.2021.660541 |
Ejemplares similares
-
Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022) -
Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states
por: Qu, Xinyao, et al.
Publicado: (2022) -
Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study
por: Wang, Yanli, et al.
Publicado: (2023) -
Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
por: Liu, Yan-ping, et al.
Publicado: (2022) -
A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta(®) in healthy male subjects
por: Sun, Yuanyuan, et al.
Publicado: (2022)